Effect on Cognitive Function of a Treatment With Aripiprazole

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Collaborator: Otsuka America Pharmaceutical
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Diagnosis of Schizophrenia

• score of 2-6 in the CGI-S scale at basline

• ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment

Exclusion Criteria:

• women of child bearing potential

• women pregnant or breast feeding

• patients with a score of 0,-1 or 7

• substance use